NF1 and neoplasm: This may be due, among other reasons, to tumor heterogeneity—the mutation might not be present in all its cells—or to the loss of some tumor suppressor genes, such as PTEN and NF1, which causes primary resistance to BRAFi/MEKis, as described below [5].